Establishing a Non-Viral Manufacturing Process for Chimeric Antigen Receptor (CAR)-T Therapies

Explore a groundbreaking webinar that addresses critical manufacturing challenges in CAR-T cell therapy development. Learn about innovative non-viral approaches to producing chimeric antigen receptor T-cell therapies, focusing on cost-effective alternatives to traditional viral vector methods. Discover how electroporation and mechanoporation techniques, combined with the sleeping beauty transposon-transposase system, can potentially reduce manufacturing costs from the current $500,000 per therapeutic dose. Examine scalable manufacturing processes that ensure stable integration of CAR transgenes while maintaining clinical efficacy for hematological malignancies treatment. Gain insights into advanced gene delivery platforms that could revolutionize the accessibility of CAR-T therapies by significantly lowering production costs. Understand the technical aspects of non-viral gene delivery systems and their application in developing more affordable cell and gene therapy products. The presentation covers practical implementation strategies for establishing scalable, cost-effective CAR-T manufacturing processes using cutting-edge biotechnology approaches. Presented by Dr. Pedro Silva Couto, a specialist in advanced therapy manufacturing with extensive experience in cell isolation, electroporation, and mechanoporation technologies for the cell and gene therapy sector.